Importantly, we provided clinical and in vitro evidence of the underrepresentation in ctDNA of mutations in promoter regions such as those of TERT and DPH3. All these findings need to be considered for the clinical implementation of ctDNA as a monitoring tool for melanoma. The gene discussed is TERT; the disease is melanoma.